State Street’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.9M | Buy |
4,512,028
+128,622
| +3% | +$557K | ﹤0.01% | 2432 |
|
|
2025
Q4 | $15.6M | Buy |
4,383,406
+1,096,288
| +33% | +$6.72M | ﹤0.01% | 2392 |
|
|
2025
Q3 | $29.3M | Buy |
3,287,118
+338,310
| +11% | +$3.43M | ﹤0.01% | 2030 |
|
|
2025
Q2 | $27.2M | Sell |
2,948,808
-265,448
| -8% | -$2.27M | ﹤0.01% | 2017 |
|
|
2025
Q1 | $27.6M | Buy |
3,214,256
+802,327
| +33% | +$7.58M | ﹤0.01% | 1951 |
|
|
2024
Q4 | $25.9M | Sell |
2,411,929
-654,018
| -21% | -$5.03M | ﹤0.01% | 2078 |
|
|
2024
Q3 | $17.4M | Sell |
3,065,947
-674,409
| -18% | -$3.89M | ﹤0.01% | 2291 |
|
|
2024
Q2 | $15.8M | Sell |
3,740,356
-3,558,651
| -49% | -$14.4M | ﹤0.01% | 2289 |
|
|
2024
Q1 | $37.2M | Buy |
7,299,007
+3,656,305
| +100% | +$20.6M | ﹤0.01% | 1877 |
|
|
2023
Q4 | $33.9M | Buy |
3,642,702
+17,253
| +0.5% | +$119K | ﹤0.01% | 1912 |
|
|
2023
Q3 | $23.7M | Sell |
3,625,449
-783,488
| -18% | -$6.24M | ﹤0.01% | 2059 |
|
|
2023
Q2 | $35.8M | Sell |
4,408,937
-1,268,439
| -22% | -$10.9M | ﹤0.01% | 1864 |
|
|
2023
Q1 | $48.7M | Sell |
5,677,376
-135,229
| -2% | -$1.35M | ﹤0.01% | 1668 |
|
|
2022
Q4 | $53.8M | Buy |
5,812,605
+1,451,167
| +33% | +$15.5M | ﹤0.01% | 1584 |
|
|
2022
Q3 | $45M | Sell |
4,361,438
-127,807
| -3% | -$1.35M | ﹤0.01% | 1658 |
|
|
2022
Q2 | $44.9M | Sell |
4,489,245
-1,088,011
| -20% | -$10.3M | ﹤0.01% | 1721 |
|
|
2022
Q1 | $68.7M | Buy |
5,577,256
+1,743,222
| +45% | +$21.4M | ﹤0.01% | 1562 |
|
|
2021
Q4 | $66.5M | Sell |
3,834,034
-331,386
| -8% | -$6.3M | ﹤0.01% | 1608 |
|
|
2021
Q3 | $74.8M | Buy |
4,165,420
+93,447
| +2% | +$1.86M | ﹤0.01% | 1500 |
|
|
2021
Q2 | $93.1M | Buy |
4,071,973
+1,324,794
| +48% | +$19.6M | ﹤0.01% | 1354 |
|
|
2021
Q1 | $41.1M | Buy |
2,747,179
+1,872,614
| +214% | +$20.5M | ﹤0.01% | 1891 |
|
|
2020
Q4 | $4.72M | Sell |
874,565
-15,925
| -2% | -$83.9K | ﹤0.01% | 2992 |
|
|
2020
Q3 | $4.05M | Buy |
890,490
+14,119
| +2% | +$60.8K | ﹤0.01% | 2882 |
|
|
2020
Q2 | $4.31M | Buy |
876,371
+53,594
| +7% | +$203K | ﹤0.01% | 2830 |
|
|
2020
Q1 | $2.59M | Buy |
822,777
+14,767
| +2% | +$51.4K | ﹤0.01% | 2943 |
|
|
2019
Q4 | $2.09M | Buy |
808,010
+24,084
| +3% | +$63.2K | ﹤0.01% | 3233 |
|
|
2019
Q3 | $2.48M | Buy |
783,926
+149,644
| +24% | +$432K | ﹤0.01% | 3141 |
|
|
2019
Q2 | $2.14M | Buy |
634,282
+581,621
| +1,104% | +$1.81M | ﹤0.01% | 3217 |
|
|
2019
Q1 | $161K | Sell |
52,661
-1,143
| -2% | -$2.73K | ﹤0.01% | 3594 |
|
|
2018
Q4 | $84K | Sell |
53,804
-1,362
| -2% | -$3.09K | ﹤0.01% | 3647 |
|
|
2018
Q3 | $151K | Sell |
55,166
-17,057
| -24% | -$48.1K | ﹤0.01% | 3619 |
|
|
2018
Q2 | $189K | Sell |
72,223
-593,610
| -89% | -$1.66M | ﹤0.01% | 3574 |
|
|
2018
Q1 | $1.84M | Buy |
665,833
+41,194
| +7% | +$116K | ﹤0.01% | 3203 |
|
|
2017
Q4 | $2.01M | Buy |
624,639
+17,459
| +3% | +$68.7K | ﹤0.01% | 3181 |
|
|
2017
Q3 | $2.52M | Buy |
607,180
+3,854
| +0.6% | +$17.1K | ﹤0.01% | 3109 |
|
|
2017
Q2 | $3.21M | Buy |
603,326
+79,516
| +15% | +$460K | ﹤0.01% | 2935 |
|
|
2017
Q1 | $3.01M | Buy |
523,810
+132,745
| +34% | +$686K | ﹤0.01% | 2935 |
|
|
2016
Q4 | $1.55M | Buy |
391,065
+83,716
| +27% | +$298K | ﹤0.01% | 3184 |
|
|
2016
Q3 | $1.11M | Buy |
307,349
+218,377
| +245% | +$919K | ﹤0.01% | 3162 |
|
|
2016
Q2 | $544K | Buy |
88,972
+69,172
| +349% | +$334K | ﹤0.01% | 3378 |
|
|
2016
Q1 | $97K | Buy |
19,800
+1,200
| +6% | +$5.28K | ﹤0.01% | 3560 |
|
|
2015
Q4 | $103K | Buy |
+18,600
| New | +$132K | ﹤0.01% | 3548 |
|
Other funds holding AVXL
VCM
SF
VPM
State Street's AVXL Position: Q1 2026 in Review
State Street increased its Anavex Life Sciences (AVXL) stake by 2.9% in Q1 2026, buying an estimated $557K and bringing the position to 4,512,028 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2432.
State Street first reported a position in AVXL in Q4 2015 and has held it in 42 quarters since. The position peaked at $93.1M in Q2 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.
- State Street held 4,512,028 shares of Anavex Life Sciences worth $13.9M as of Q1 2026.
- State Street bought 128,622 Anavex Life Sciences shares in Q1 2026, an estimated $557K.
- Anavex Life Sciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2432 holding.
- State Street first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 42 quarters since.
- State Street's Anavex Life Sciences position peaked at $93.1M in Q2 2021.
- 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.